William W. Brooke net worth and biography

William Brooke Biography and Net Worth

Director of MaxCyte

Will Brooke has served on our Board since 2004. Mr. Brooke retired from Harbert Management Corporation (HMC) in December 2021, having served in various capacities since he co-founded HMC in 1993.

He most recently served as executive vice president and limited partner prior to his retirement from HMC and also served as managing partner of HMC’s venture capital funds family from 2003 to 2014. Mr. Brooke has been advising and investing in early-stage and growth companies for more than 30 years and previously served on the boards of numerous pharmaceutical and medical equipment companies such as nContact, Inc., NovaMin Technology, Inc., and Emageon Corporation.

Since December 2018, he has also served as a board member of KPX, LLC, an environmental, social and governance advisory firm serving the investment and advisory sectors. Prior to joining HMC, Mr. Brooke practiced law for a decade. Mr. Brooke received a BS in business management and a JD from the University of Alabama.

Our Board believes Mr. Brooke’s extensive business experience and deep financial knowledge qualify him to serve as a director.

What is William W. Brooke's net worth?: The estimated net worth of William W. Brooke is at least $203.69 thousand as of August 13th, 2025. Mr. Brooke owns 150,879 shares of MaxCyte stock worth more than $203,687 as of August 25th. This net worth approximation does not reflect any other investments that Mr. Brooke may own. Learn More about William W. Brooke's net worth.
How do I contact William W. Brooke?: The corporate mailing address for Mr. Brooke and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on William W. Brooke's contact information.
Has William W. Brooke been buying or selling shares of MaxCyte?: William W. Brooke has not been actively trading shares of MaxCyte within the last three months. Most recently, on Wednesday, August 13th, William W. Brooke bought 50,000 shares of MaxCyte stock. The stock was acquired at an average cost of $1.29 per share, with a total value of $64,500.00. Following the completion of the transaction, the director now directly owns 150,879 shares of the company's stock, valued at $194,633.91. Learn More on William W. Brooke's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes William Brooke (Director), Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, insiders at the sold shares 1 times. They sold a total of 10,142 shares worth more than $8,215.02. The most recent insider tranaction occured on March, 17th when CFO Douglas J Swirsky sold 10,142 shares worth more than $8,215.02. Insiders at MaxCyte own 4.1% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 3/17/2026.

William W. Brooke Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/13/2025	Buy	50,000	$1.29	$64,500.00	150,879

William W. Brooke Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.35

$1.34

$1.39

50 Day Range

MA: $1.22

$1.01

$1.42

2 Week Range

Now: $1.35

$0.64

$1.87

Volume

310,487 shs

Average Volume

1,098,864 shs

Market Capitalization

$139.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48